FDA Clears Potential IPF Therapy, IM156, for Phase 1 Trial

FDA Clears Potential IPF Therapy, IM156, for Phase 1 Trial

286268

FDA Clears Potential IPF Therapy, IM156, for Phase 1 Trial

The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ImmunoMet Therapeutics‘ treatment candidate for idiopathic pulmonary fibrosis (IPF), IM156. The decision grants ImmunoMet permission to open studies of the therapy in people in the U.S. “FDA clearance of an IND for IM156 is a major milestone for ImmunoMet,” Benjamin Cowen, CEO of ImmunoMet, said in a press release. The company now plans to initiate a single-site Phase 1…

You must be logged in to read/download the full post.